Dean L. Kellogg, Jr., MD, Ph.D.

Federal

Funding Agency Claude D. Pepper Older Americans Independence Center Title NAD Modulation to Improve Cognition in Mild Cognitive Impairment (MCI) Status Active Period 5/2016 - Present Role Co-Investigator Grant Detail Currently there are no effective treatment options for patients with Alzheimer?s disease (AD), the most common cause of dementia and sixth leading cause of death in the United States. This reality is especially devastating to patients with mild cognitive impairment (MCI), a clinical diagnosis of declining memory performance that often precedes AD. While patients with MCI experience waning cognitive performance, they independently carry out tasks of daily living. As such, successful intervention at this stage would allow maintained independence, and prevent their progression to an incurable deadly disease, AD. Based on preclinical studies in model organisms, maintaining levels of nicotinamide adenine dinucleotide (NAD+) is a promising approach to sustain cognitive performance and overall health. NAD(+) is a coenzyme that has proven to enhance lifespan and healthspan in model organisms ranging from worms to non-human primates, and preserve cognitive health in animal models of AD. NAD(+) can be synthesized from dietary intake of its precursors, including nicotinamide riboside, a readily available non-prescription nutritional supplement. In this pilot study we propose an eight week, double-blind, randomized, placebo controlled trial with one such supplement, Basis (Elysium Health). We will test the efficacy of NAD(+) supplementation on brain function through cognitive assessment and functional MRI. We hypothesize that NAD(+) replenishment will enhance brain blood flow assessed by fMRI, and these improvements will be associated with improved cognitive performance. Results from our pilot study will provide information regarding the effect of NAD(+) therapy on cognitive function, and will serve as preliminary data for future large scale clinical trials. Funding Agency Claude D. Pepper OAIC Title South Texas Aging and Research Repository Status Active Period 5/2016 - Present Role Co-Investigator Grant Detail   Funding Agency VA RR&D Title Vasomotor and Sudomotor Activity During Heat Stress in Spinal Cord Injury Status Active Period 1/2017 - 12/2022 Role Co-Principal Investigator Grant Detail This project tests the hypothesis that separate neural pathways effect cutaneous vasodilation and sweating as manifested by separate responses near the level of injury in spinal cord injured humans. Funding Agency NIH/NHLBI Title Pathobiology of Occlusive Vascular Disease (Program Director - James Stockand) Status Active Period 9/2007 - 8/2022 Role Contributor Grant Detail This NIH training grant supports postdoctoral training in the area of occlusive cardiovascular disease, inflammation, and degenerative disorders of cardiovascular tissues. Funding Agency National Institute on Aging Title Metformin for Preventing Frailty in High Risk Older Adults Status Active Period 6/2017 - 5/2022 Role Co-Investigator Grant Detail Pre-diabetes/insulin resistance and inflammation are major contributors to frailty. This study will determine whether the use of metformin to modulate pre-diabetes/insulin resistance and inflammation in older adults with pre-diabetes will prevent and/or ameliorate the progression of frailty. Funding Agency NIA Title San Antonio Claude D. Pepper Older Americans Independence Center (P30) Status Active Period 6/2015 - 4/2020 Role Co-Investigator Grant Detail http://sapepper.barshop.uthscsa.edu/clinical-research-core-crc/ Funding Agency Claude D. Pepper OAIC Title Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis Status Active Period 7/2017 - 11/2019 Role Co-Investigator Grant Detail  

State

Funding Agency Pepper Center Title Effect of mTOR inhibition and other metabolism modulating interventions on the elderly supplement: cardiovascular effects Status Complete Period 10/2017 - 10/2018 Role Co-Principal Investigator Grant Detail   Funding Agency Nathan Shock Center Title Rapamycin and acarbose in the elderly: Effects on inflammation and the microbiome Status Active Period 7/2017 - 6/2018 Role Co-Principal Investigator Grant Detail   Funding Agency CTSA Title Acarbose as a safe and effective modulator of aging deficites in geriatric subjects Status Complete Period 12/2016 - 11/2017 Role Co-Principal Investigator Grant Detail   Funding Agency Pepper Center (NIH pilot) Title Effect of mTOR inhibition and other metabolism modulating interventions on the elderly: Immune, Cognitive and Functional consequences Status Complete Period 6/2016 - 5/2017 Role Co-Principal Investigator Grant Detail This pilot grant will assess the effect of rapamycin in elderly human subjects; the focus will be on the gut microbiome and immune parameters.